Author's Reply to De Ponti et al.: "Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus''

被引：0

作者：

Scheen, Andre J. ^{[1
,2
]}

机构：

[1] Univ Liege, Ctr Interdisciplinary Res Med, Div Clin Pharmacol, B-4000 Liege, Belgium

[2] Univ Liege, CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium

来源：

CLINICAL PHARMACOKINETICS | 2015年 / 54卷 / 04期

关键词：

HEPATOTOXICITY; VILDAGLIPTIN; TOLERABILITY; EVENTS; DRUGS;

D O I：

10.1007/s40262-015-0249-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：449 / 451

页数：3

共 50 条

[1] Author’s Reply to De Ponti et al.: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
André J. Scheen
Clinical Pharmacokinetics, 2015, 54 : 449 - 451
[2] Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
Scheen, Andre J.
CLINICAL PHARMACOKINETICS, 2014, 53 (09) : 773 - 785
[3] Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
André J. Scheen
Clinical Pharmacokinetics, 2014, 53 : 773 - 785
[4] Comment on: "Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus''
Raschi, Emanuel
Poluzzi, Elisabetta
De Ponti, Fabrizio
CLINICAL PHARMACOKINETICS, 2015, 54 (04) : 447 - 448
[5] Erratum to: Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
André J. Scheen
Clinical Pharmacokinetics, 2014, 53 : 1061 - 1061
[6] Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
Emanuel Raschi
Elisabetta Poluzzi
Fabrizio De Ponti
Clinical Pharmacokinetics, 2015, 54 : 447 - 448
[7] Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus (vol 53, pg 773, 2014)
Scheen, Andre J.
CLINICAL PHARMACOKINETICS, 2014, 53 (11) : 1061 - 1061
[8] Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, Matthew P.
Pratley, Richard E.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 : S309 - S318
[9] Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Gilbert, Matthew P.
Pratley, Richard E.
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (06): : 11 - 24
[10] Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes
André J. Scheen
Clinical Pharmacokinetics, 2015, 54 : 1 - 21

← 1 2 3 4 5 →